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have investigated the utility of pharmacotherapy and epidural steroid injections (ESI) 
in large practice setting. We sought to gather comprehensive data about the char-
acteristics, efficacy, tolerability and quality of life (QoL) of patients with LBP with 
these therapies. Methods: Information was collected on a standardized form. 
Information included patient characteristics, type and duration of therapies, adverse 
events, pain relief using visual analogue scale (VAS) and QoL by measuring disability 
using modified ODQ at each month of follow-up. Results: Consecutive 81 patients 
were recruited and followed for 6 months. Average baseline pain duration was found 
to be 45.5 months. Combination of drugs and ESI was given in 75 (92%) patients. 
Anticonvulsants (75%) and Antidepressants (57%) were most commonly prescribed 
medications. Change in VAS & ODQ score from baseline to each follow-up at 3 months 
(VAS - 15), 6 months (VAS -25) was significantly (P < 0.05) improved. ConClusions: 
Pregabalin and amitriptyline were most commonly used drugs with maximum pain 
relief and improved Qol. Desired pain relief fluctuated with time. ESI can be promising 
choice when desirable pain relief is not achieved with medications.
SyStemic DiSorDerS/conDitionS – Health care Use & Policy Studies
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objeCtives: To evaluate the benefit-risk of biological agents (BA) in the treatment of 
moderate to severe psoriasis. Methods: It was performed a mixed treatment com-
parison (MTC) based on all available clinical trials of psoriasis treated with BA. The 
common agent comparator was placebo and the time-horizon was up to 24 weeks 
of treatment. This indirect meta-analysis was followed by a stochastic multicriteria 
acceptability analysis (SMAA) to compare adalimumab, etanercept, infliximab and 
ustekinumab on two benefit and two risk criterias. Efficacy was evaluated by means 
of Psoriasis Area Severity Index 90 and 75 response (rPASI90 and rPASI75, respectively) 
and the risks corresponded to any adverse event (AAE) and serious adverse event 
(SAE). MTC/SMAA analysis was performed for two scenarios: one with missing out-
come preference and the other with ordinal preference information established 
by experts in psoriasis (SAE > rPASI90 > rPASI75 > AAE). Results: Results show 
the same tendency for both created scenarios. Infliximab 5 mg/kg had the highest 
probability of being the 1st-place in MTC/SMAA ranking (84% to 67%). It was followed 
by ustekinumab 90 mg for the 2nd-place (54% to 50%), ustekinumab 45 mg for the 
3rd-place (51% - 50%), adalimumab 80 mg followed by 40 mg (51% - 47%), etanercept 
50 mg TW (74% to 62%) and placebo in the 6th-place(97% - 94%). ConClusions: 
From all available evidence on treatment with BA for psoriasis, the designed method 
was enabled to point that infliximab 5 mg/kg is the BA with the highest probability 
of having the best benefit-risk ratio in the short-term follow up. It is followed by 
ustekinumab 90mg, ustekinumab 45 mg, adalimumab 80--> 40 mg, etanercept 50 
mg TW and placebo, respectively. Our findings can be useful to help on deciding 
which sequence of BA must be defined by guidelines and health services when 
therapy failure happens.
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objeCtives: To describe patient characteristics and costs associated with first year 
biologic therapy use in psoriasis patients who switched or remained on biologic 
therapy. Methods: Adult patients with psoriasis diagnosis (ICD-9 CM 696.1 or 696.8 
codes, excluding psoriatic arthritis (ICD-9-CM 696.0), rheumatoid arthritis(ICD-9-CM 
714.x), ankylosing spondylitis(ICD-9-CM 720.0), Crohn’s disease(ICD-9-CM 555.x) or 
ulcerative colitis(ICD-9-CM 556.x)) with continuous insurance coverage for one year 
pre and post first biological therapy prescription, having at least one prescription of 
adalimumab, etanercept, infliximab or ustekinumab and no previous use of biologic 
were selected from a privately insured MarketScan® commercial and Medicare 
database, 2012 . Two patient cohorts of switchers and non-switchers were defined 
based on gap of 60 days of therapeutic benefit. Analyses included descriptive sta-
tistics and per member per year costs. Results: Of the 2848 patients who met the 
study criteria, 8.32% (n= 237) switched(S) to another biologic therapy, 1305 (45.82%) 
remained on initial biologic therapy (non-switched (NS)) and 1,306 (45.86%) discon-
tinued their treatment within the first year of initiating biologic therapy. The mean 
age(SD) was 46.9(13.3) years with a higher percentage of males in the non-switched 
group than switched and discontinued groups (59.4% vs. 51.1% and 52.5%, respec-
tively). One year post start of biologic therapy, total health care cost per patient 
(S: US$38,529(24,328), NS: US$32,822(15,913)), all cause hospitalization cost per 
patient (S: US$1713(12,528), NS: US$911(4663)) and all cause emergency room cost 
per patient (S: US$447 (1300), NS: US$266 (1000)) were higher among patients who 
switched to another biologic therapy than among patients who remained on their 
initial biologic therapy. ConClusions: Although few patients switched from their 
initial biologic therapy within first year of initiating treatment, higher direct health 
care costs were observed in this patient group compared to those who remained 
on their initial therapy. These results suggest an unmet need among patients that 
switch biologic therapies in psoriasis.
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de Behcet y tratamiento farmacológico. La evaluación farmacoeconómica se llevó a 
cabo, utilizando un modelo de efecto fijo, desde la perspectiva de un paciente adulto, 
con sistema previsional de salud público, EB activa y las manifestaciones clínicas 
seleccionadas, diagnosticado según el criterio del International Study Group, en 
un horizonte temporal de un año. El análisis de decisión para las dos alternativas 
más efectivas se llevó a cabo a través de DATA 3.5. ResultAdos: De los 38 estu-
dios encontrados en cada una de las bases de datos, 15 cumplieron los criterios de 
selección, con los cuales se calculó el efecto de la intervención. Las alternativas más 
efectivas resultaron ser talidomida de 100 y 300 mg y la suspensión de sucralfato. 
Una vez realizado el análisis costo-efectividad, la suspensión de sucralfato fue domi-
nada por talidomida de 100 mg. ConClusiones: A pesar de la falta de evidencia en 
enfermedades raras y eficacia de tratamientos clásicos, fue posible proponer una 
alternativa costo-efectiva para la EB. No obstante, dada la heterogeneidad de las 
manifestaciones clínicas en enfermedades raras y los costos de los tratamientos, 
resulta necesario proponer análisis alternativos a la costo-efectividad, que permitan 
apoyar a toma de decisiones para estos grupos de pacientes.
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intRoduCtion: La Federación Mundial de la Hemofilia indica que existen regis-
trados 137.352 pacientes hemofílicos en 77 países, sin embargo se estima que deben 
existir cerca de 400.000 personas en todo el mundo. Un reciente estudio de carga 
de enfermedad genética estima que existirían 2931 colombianos con hemofilia, 
considerando el período de 1996 a 2025. objeCtivos: Evaluar la costo-efectivi-
dad de tres tratamientos: Kogenate, Advate y Recombinate para el tratamiento de 
Hemofilia tipo A Severa en una población de 1 a 78 años. Describir los resultados 
de pacientes con Hemofilia Severa que reciben profilaxis con distintos productos 
del Factor VIII. MetodologíAs: Se adaptó un modelo de Markov que describe 
la historia natural y los resultados de la Hemofilia A Severa. El modelo considera 
siete estados de salud caracterizados por el estado del inhibidor (3 niveles: HR, LR, 
Ninguno), daño articular (Si o no) y la muerte (estado absorbente). ResultAdos: 
Um total de 1.186 pacientes con Hemofilia A, lo que representaría una prevalencia 
del 0,009% dentro de la población afiliada. La ganancia en términos de AVACs es 
similar para los tres tratamientos. Los componentes con el mayor impacto en los 
costos son profilaxis y control de sangrado. Del análisis de sensibilidad determin-
istico, el parámetro con el mayor impacto es la dosis de Advate con profilaxis. Del 
análisis de sensibilidad probabilísticos, Kogenate es una alternativa dominante 
respecto a Advate en 45% de las simulaciones, y en 70.4% de las simulaciones 
respecto a Recombinate. ConClusiones: Se encontró que los costos de Kogenate 
y Recombinate son en su mayoría atribuidos a la profilaxis y aquellos a Advate al 
tratamiento de sangrado. Aunque la eficacia clínica de los productos es similar, las 
diferencias en la incidencia del desarrollo del inhibidor significan menores costos 
y mejor calidad de vida para los pacientes que son tratados con Kogenate.
SyStemic DiSorDerS/conDitionS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: To investigate family burden, awareness and treatment status of 
ß-thalassemia patients in China. Methods: The families with major ß-thalas-
semia received investigation. The questionnaire involved medical management of 
ß-thalassemia, economic burden, life quality and recognition, attitude and behav-
ior of the relatives to the disease. Results: Currently, the mainstay treatment 
of major thalassemia remains transfusion and deferrization therapy, so that the 
treatment cost is about 60,000 to 70,000 RMB per year for a 10-year-old-child and 
this number even rises with the increasing of the age. Therefore, the family burden 
and life quality of the patients is significantly involved during the treatment of 
this disease. Among different diferrization treatment, deferasirox was first choice 
of the patients concerning the cost-effect factors and lower incidence of adverse 
events, exemplified as local injection reactions which are commonly occurred in 
the patients receiving desferrioxamine. Most of the patients chose the convenience 
as the most important factor for the compliance to the treatment. And in addition 
to disease related factors and symptoms as discussed below, convenience was also 
considered as important issue for life quality. Although until now, 70.7% of the 
patients received intravenous desferrioxamine treatment, over half of the patients 
would like to change to a more convenient oral deferrization treatment, and def-
erasirox was considered as the first choice due to the low price of this medicine in 
China. ConClusions: ß-thalassemia as a hereditary disease severely influenced 
the life quality of the patients, increased economic and social burden to the family. 
The medical utility and society should pay more care to the patients and their fami-
lies, especially the grass-root ones. The government should take the responsibility 
to improve the medical reimbursement system for this disease.
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objeCtives: Substantial number of patients with persistent low back pain (LBP) 
are treated with multimodal spectrum of conservative and invasive therapies. Few 
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objeCtives: Toxocariasis is a anthropozoonosis that occurs in various regions of the 
world, often found in developing countries and in regions where sanitation conditions 
are poor. This disease affects dogs and cats, whose etiologic agents are, respectively, 
Toxocara canis and cati. These mammals are the definitive hosts of this geohelminth 
and a person it’s a paratenic host. Infection in humans can cause acute clinical sever-
ity varied and eventually chronicity. The diagnosis is made by means of the ELISA and 
the classical treatment is done with benzimidazole anthelmintics. The toxocariasis, 
despite not being on the list of neglected diseases of WHO, has aroused little interest 
in academia and even less in health services, despite its prevalence in various regions 
of Brazil. Some studies have discussed the possible association between parasitic 
infections and allergic / atopic diseases and asthma, working with the hypothesis 
that exert immunomodulatory role. To review the literature on the current prevalence 
of toxocariasis in Brazil and its association with other diseases. Methods: A search 
was performed in electronic databases, Medline, Lilacs, PubMed and Embase. The 
words were: “toxocariasis and Brazil”, in the period from 2008 to 2013, and found 
406 articles, with the inclusion criteria of studies done with humans and presenting 
epidemiological aspects. Results: We selected 90 articles that prove the current high 
prevalence of toxocariasis in various regions, ranging from 11.1% to 65.4%. Several 
studies point to an association of toxocariasis with other diseases of high public 
health relevance. Despite this evidence the Brazilian Public Health System does not 
repayment diagnostic tests for the detection of anti-Toxocara, complicating the clini-
cal and leading to no treatment. ConClusions: The review provides grants for the 
revision of public policies for prevention, diagnosis and treatment of toxocariasis.
bACkgRound: As many orphan drug (OD) manufacturers expand their businesses 
across emerging markets(EM) they are faced with restrictive and often non-exist-
ent funding pathways. As a result pricing and reimbursement (P&R) negotiations 
remain very challenging, pushing manufactures to explore the value of local clini-
cal development in supporting access. objeCtives: To a) understand the value of 
local clinical development for payers, to support reimbursement in Chile, and b) 
compare and contrast against four other emerging markets: Russia, Turkey, India 
and China. Methods: In-depth interviews were conducted with 3 stakeholders 
per market including national payers, reimbursement committee advisors and rare 
diseases clinical specialists, to understand a) Current OD funding pathways; b) P&R 
decision drivers; and c) Impact of local development on reimbursement. Selected 
value drivers were used to develop a scale and qualitatively measure the risk/
reward analysis of local clinical development on OD access. Results: The impact 
of local development on OD reimbursement varies across markets. Respondents 
in Chile (n= 3) highlighted that clinical development will have a strong influence 
on future willingness to pay, but the opportunity will remain small due to lack 
of clarity around long-term funding. In Turkey (n= 3), providing access to patients 
through compassionate use schemes, prior to obtaining registration, positively 
impacts reimbursement.While in Russia, conducting a local clinical trial adds no 
value to the P&R decision process as cited by payers (n= 3). As for India and China 
where price remains the overriding factor, respondents (n= 6) stated that national 
reimbursement remains a distant prospect. ConClusions: High clinical experts’ 
awareness, strong influence of advocacy groups and developing OD funding path-
ways renders Chile and Turkey the most attractive EM for local development. 
While in comparison, the generation of local patient data is also favoured across 
the remaining markets, price remains the overriding factors influencing access 
and reimbursement.
